Indmedica - India's Premier Medical Portal - Cyber Lectures

 

International Standards for Tuberculosis Care

Developed by the Tuberculosis Coalition for Technical Assistance (TBCTA)

Page 17

Topics

References:

  1. Hopewell PC, Pai M. Tuberculosis, vulnerability, and access to quality care. JAMA 2005;293(22):2790–3.
  2. World Health Organization. Guidelines for WHO Guidelines. Geneva: World Health Organization,
    2003: 1-24.
  3. Hadley M, Maher D. Community involvement in tuberculosis control: lessons from other health care
    programmes. Int J Tuberc Lung Dis 2000;4(5):401–8.
  4. World Health Organization. Guidelines for the prevention of tuberculosis in health care facilities in
    resource-limited settings. Geneva: World Health Organization, 1999.
  5. Centers for Disease Control and Prevention. Guidelines for preventing the transmission of Mycobacterium
    tuberculosis in health-care settings, 2005. MMWR 2005;54(RR-17):1–141.
  6. World Health Organization. Global tuberculosis control. Surveillance, planning, fi nancing. WHO Report
    2005. Geneva: World Health Organization, 2005: 1–247.
  7. Corbett EL, Watt CJ, Walker N, et al. The growing burden of tuberculosis: global trends and interactions
    with the HIV epidemic. Arch Intern Med 2003;163(9):1009–21.
  8. Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC. Consensus statement. Global burden of tuberculosis:
    estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and
    Monitoring Project. JAMA 1999;282(7):677–86.
  9. Dye C, Watt CJ, Bleed DM, Hosseini SM, Raviglione MC. The evolution of tuberculosis control, and
    prospects for reaching the millennium development goals. JAMA 2005;293:2767–75.
  10. Uplekar M. Involving private health care providers in delivery of TB care: global strategy. Tuberculosis
    2003;83(1-3):156–64.
  11. Uplekar M, Pathania V, Raviglione M. Private practitioners and public health: weak links in tuberculosis
    control. Lancet 2001;358(9285):912–6.
  12. World Health Organization. Involving private practitioners in tuberculosis control: issues, interventions,
    and emerging policy framework. Geneva: World Health Organization, 2001: 1–81.
  13. World Health Organization. Public-private mix for DOTS. Practical tools to help implementation.
    Geneva: World Health Organization, 2003.
  14. Cheng G, Tolhurst R, Li RZ, Meng QY, Tang S. Factors affecting delays in tuberculosis diagnosis
    in rural China: a case study in four counties in Shandong Province. Trans R Soc Trop Med Hyg
    2005;99(5):355–62.
  15. Lonnroth K, Thuong LM, Linh PD, Diwan VK. Delay and discontinuity—a survey of TB patients’ search
    of a diagnosis in a diversifi ed health care system. Int J Tuberc Lung Dis 1999;3(11):992–1000.
  16. Olle-Goig JE, Cullity JE, Vargas R. A survey of prescribing patterns for tuberculosis treatment
    amongst doctors in a Bolivian city. Int J Tuberc Lung Dis 1999;3(1):74–8.
  17. Prasad R, Nautiyal RG, Mukherji PK, Jain A, Singh K, Ahuja RC. Diagnostic evaluation of pulmonary
    tuberculosis: what do doctors of modern medicine do in India? Int J Tuberc Lung Dis 2003;7(1):52–7.
  18. Shah SK, Sadiq H, Khalil M, et al. Do private doctors follow national guidelines for managing pulmonary
    tuberculosis in Pakistan? East Mediterr Health J 2003;9(4):776–88.
  19. Singla N, Sharma PP, Singla R, Jain RC. Survey of knowledge, attitudes and practices for tuberculosis
    among general practitioners in Delhi, India. Int J Tuberc Lung Dis 1998;2(5):384–9.
  20. Suleiman BA, Houssein AI, Mehta F, Hinderaker SG. Do doctors in north-western Somalia follow the
    national guidelines for tuberculosis management? East Mediterr Health J 2003;9(4):789–95.
  21. Uplekar MW, Shepard DS. Treatment of tuberculosis by private general practitioners in India. Tubercle
    1991;72(4):284–90.
  22. World Health Organization. Toman’s tuberculosis: case detection, treatment, and monitoring (second
    edition). Geneva: World Health Organization, 2004: 1–332.
  23. WHO/IUATLD/KNCV. Revised international defi nitions in tuberculosis control. Int J Tuberc Lung Dis
    2001;5(3):213–5.
  24. World Health Organization. Treatment of tuberculosis. Guidelines for national programmes. Geneva:
    World Health Organization, 2003.
  25. Enarson DA, Rieder HL, Arnadottir T, Trebucq A. Management of tuberculosis. A guide for low income
    countries. 5th edition. Paris: International Union Against Tuberculosis and Lung Disease, 2000.
  26. World Health Organization. Respiratory care in primary care services: a survey in 9 countries. Geneva:
    World Health Organization, 2004.
  27. Luelmo F. What is the role of sputum microscopy in patients attending health facilities? In: Frieden
    TR, ed. Toman’s tuberculosis. Case detection, treatment and monitoring, 2nd Edition. Geneva:
    World Health Organization, 2004: 7–10.
  28. Organizacion Panamericana de la Salud. Control de Tuberculosis en America Latina: Manual de Normas
    y Procedimientos para programas Integrados. Washington, D.C.: Organizacion Panamericana
    de la Salud, 1979.
  29. Santha T, Garg R, Subramani R, et al. Comparison of cough of 2 and 3 weeks to improve detection
    of smear-positive tuberculosis cases among out-patients in India. Int J Tuberc Lung Dis
    2005;9(1):61–8.
  30. Khan J, Malik A, Hussain H, et al. Tuberculosis diagnosis and treatment practices of private physicians
    in Karachi, Pakistan. East Mediterr Health J 2003;9(4):769–75.
  31. Harries AD, Hargreaves NJ, Kemp J, et al. Deaths from tuberculosis in sub-Saharan African countries
    with a high prevalence of HIV-1. Lancet 2001;357(9267):1519–23.
  32. Maher D, Harries A, Getahun H. Tuberculosis and HIV interaction in sub-Saharan Africa: impact on
    patients and programmes; implications for policies. Trop Med Int Health 2005;10(8):734–42.
  33. Mukadi YD, Maher D, Harries A. Tuberculosis case fatality rates in high HIV prevalence populations
    in sub-Saharan Africa. AIDS 2001;15(2):143–52.
  34. Harries A. What is the additional yield from repeated sputum examinations by microscopy and culture?
    In: Frieden TR, ed. Toman’s tuberculosis. Case detection, treatment and monitoring, 2nd Edition.
    Geneva: World Health Organization, 2004: 46–50.
  35. Mase S, Ng V, Henry MC, et al. Yield of serial sputum smear examinations in the evaluation of
    pulmonary tuberculosis: a systematic review (unpublished report). Geneva: Special Programme for
    Research & Training in Tropical Diseases (TDR), World Health Organization, and Foundation for Innovative
    New Diagnostics (FIND). 2005.
  36. Rieder HL, Chiang CY, Rusen ID. A method to determine the utility of the third diagnostic and the
    second follow-up sputum smear examinations to diagnose tuberculosis cases and failures. Int J
    Tuberc Lung Dis 2005;9(4):384–391.
  37. Gopi PG, Subramani R, Selvakumar N, Santha T, Eusuff SI, Narayanan PR. Smear examination of
    two specimens for diagnosis of pulmonary tuberculosis in Tiruvallur District, south India. Int J Tuberc
    Lung Dis 2004;8(7):824–8.
  38. Van Deun A, Salim AH, Cooreman E, et al. Optimal tuberculosis case detection by direct sputum
    smear microscopy: how much better is more? Int J Tuberc Lung Dis 2002;6(3):222–30.
  39. Sarin R, Mukerjee S, Singla N, Sharma PP. Diagnosis of tuberculosis under RNTCP: examination of
    two or three sputum specimens. Indian J Tuberc 2001(48):13–16.
  40. Steingart KR, Ng V, Henry MC, et al. Sputum processing methods to improve the sensitivity and
    yield of smear microscopy for tuberculosis: a systematic review (unpublished report). Geneva: Special
    Programme for Research & Training in Tropical Diseases (TDR), World Health Organization, and
    Foundation for Innovative New Diagnostics (FIND). 2005.
  41. Henry MC. Conventional light microscopy versus fl uorescence microscopy for the diagnosis of pulmonary
    tuberculosis: a systematic review: University of California, Berkeley, Master’s Thesis, Spring
    2005.
  42. Steingart KR, Ng V, Henry MC, et al. Fluorescence versus conventional sputum smear microscopy
    for tuberculosis: a systematic review (unpublished report). Geneva: Special Programme for Research
    & Training in Tropical Diseases (TDR), World Health Organization, and Foundation for Innovative New
    Diagnostics (FIND). 2005.
  43. Mtei L, Matee M, Herfort O, et al. High rates of clinical and subclinical tuberculosis among HIV-infected
    ambulatory subjects in Tanzania. Clin Infect Dis 2005;40(10):1500–7.
    44. Koppaka R, Bock N. How reliable is chest radiography? In: Frieden TR, ed. Toman’s tuberculosis.
    Case detection, treatment and monitoring, 2nd Edition. Geneva: World Health Organization, 2004:
    51-60.
  44. Harries A. What are the relative merits of chest radiography and sputum examination (smear microscopy
    and culture) in case detection among new outpatients with prolonged chest symptoms?
    In: Frieden TR, ed. Toman’s tuberculosis. Case detection, treatment and monitoring, 2nd Edition.
    Geneva: World Health Organization, 2004: 61–65.
  45. Nagpaul DR, Naganathan N, Prakash M. Diagnostic photofl uorography and sputum microscopy
    in tuberculosis case fi ndings. Proceedings of the 9th Eastern Region Tuberculosis Conference and
    29th National Conference on Tuberculosis and Chest Diseases 1974, Delhi.
  46. Colebunders R, Bastian I. A review of the diagnosis and treatment of smear-negative pulmonary
    tuberculosis. Int J Tuberc Lung Dis 2000;4(2):97–107.
  47. Siddiqi K, Lambert ML, Walley J. Clinical diagnosis of smear-negative pulmonary tuberculosis in lowincome
    countries: the current evidence. Lancet Infect Dis 2003;3(5):288–296.
  48. Bah B, Massari V, Sow O, et al. Useful clues to the presence of smear-negative pulmonary tuberculosis
    in a West African city. Int J Tuberc Lung Dis 2002;6(7):592–8.
  49. Oyewo TA, Talbot EA, Moeti TL. Non-response to antibiotics predicts tuberculosis in AFB-smearnegative
    TB suspects, Botswana, 1997-1999 (abstract). Int J Tuberc Lung Dis 2001(5(Suppl 1)):
    S126.
  50. Somi GR, O’Brien RJ, Mfi nanga GS, Ipuge YA. Evaluation of the MycoDot test in patients with suspected
    tuberculosis in a fi eld setting in Tanzania. Int J Tuberc Lung Dis 1999;3(3):231–8.
  51. Wilkinson D, De Cock KM, Sturm AW. Diagnosing tuberculosis in a resource-poor setting: the value
    of a trial of antibiotics. Trans R Soc Trop Med Hyg 1997;91(4):422–4.
  52. Sterling TR. The WHO/IUATLD diagnostic algorithm for tuberculosis and empiric fl uoroquinolone use:
    potential pitfalls. Int J Tuberc Lung Dis 2004;8(12):1396–400.
  53. van Deun A. What is the role of mycobacterial culture in diagnosis and case fi nding? In: Frieden TR,
    ed. Toman’s tuberculosis. Case detection, treatment and monitoring, 2nd Edition. Geneva: World
    Health Organization, 2004: 35–43.
  54. Kim TC, Blackman RS, Heatwole KM, Kim T, Rochester DF. Acid-fast bacilli in sputum smears of
    patients with pulmonary tuberculosis. Prevalence and signifi cance of negative smears pretreatment
    and positive smears post-treatment. Am Rev Respir Dis 1984;129(2):264–8.
  55. Toman K. How many bacilli are present in a sputum specimen found positive by smear microscopy?
    In: Frieden TR, ed. Toman’s tuberculosis. Case detection, treatment and monitoring, 2nd Edition.
    Geneva: World Health Organization, 2004: 11-13.
  56. Toman K. How reliable is smear microscopy? In: Frieden TR, ed. Toman’s tuberculosis. Case detection,
    treatment and monitoring, 2nd Edition. Geneva: World Health Organization, 2004: 14–22.
  57. Menzies D. What is the current and potential role of diagnostic tests other than sputum microscopy
    and culture? In: Frieden TR, ed. Toman’s tuberculosis. Case detection, treatment and monitoring,
    2nd Edition. Geneva: World Health Organization, 2004: 87–91.
  58. Pai M. The accuracy and reliability of nucleic acid amplifi cation tests in the diagnosis of tuberculosis.
    Natl Med J India 2004;17(5):233–6.
  59. Pai M, Flores LL, Hubbard A, Riley LW, Colford JM, Jr. Nucleic acid amplifi cation tests in the diagnosis
    of tuberculous pleuritis: a systematic review and meta-analysis. BMC Infect Dis 2004;4(1):6.
  60. Pai M, Flores LL, Pai N, Hubbard A, Riley LW, Colford JM, Jr. Diagnostic accuracy of nucleic acid
    amplifi cation tests for tuberculous meningitis: a systematic review and meta-analysis. Lancet Infect
    Dis 2003;3(10):633–43.
  61. Flores LL, Pai M, Colford JM, Jr., Riley LW. In-house nucleic acid amplifi cation tests for the detection
    of Mycobacterium tuberculosis in sputum specimens: meta-analysis and meta-regression. BMC
    Microbiol 2005;5:55.
  62. Nahid P, Pai M, Hopewell PC. Advances in the diagnosis and treatment of tuberculosis. Proc Am
    Thorac Soc In Press.
  63. Shingadia D, Novelli V. Diagnosis and treatment of tuberculosis in children. Lancet Infect Dis
    2003;3(10):624–32.
  64. Gie RP, Beyers N, Schaaf HS, Goussard P. The challenge of diagnosing tuberculosis in children: a
    perspective from a high incidence area. Paediatr Respir Rev 2004;5 Suppl A:S147–9.
  65. Hesseling AC, Schaaf HS, Gie RP, Starke JR, Beyers N. A critical review of diagnostic approaches
    used in the diagnosis of childhood tuberculosis. Int J Tuberc Lung Dis 2002;6(12):1038–45.
  66. Nelson LJ, Wells CD. Tuberculosis in children: considerations for children from developing countries.
    Semin Pediatr Infect Dis 2004;15(3):150–4.
  67. World Health Organization. Management of the child with a serious infection or severe malnutrition :
    guidelines for care at the fi rst-referral level in developing countries. Geneva: World Health Organization,
    2000.
  68. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society
    of America. Treatment of tuberculosis. Am J Respir Crit Care Med 2003;167(4):603–62.
  69. Gelband H. Regimens of less than six months for treating tuberculosis. Cochrane Database Syst Rev
    2000(2):CD001362.
  70. Santha T. What is the optimum duration of treatment? In: Frieden TR, ed. Toman’s tuberculosis.
    Case detection, treatment and monitoring, 2nd Edition. Geneva: World Health Organization, 2004:
    144–151.
  71. Korenromp EL, Scano F, Williams BG, Dye C, Nunn P. Effects of human immunodefi ciency virus infection
    on recurrence of tuberculosis after rifampin-based treatment: an analytical review. Clin Infect
    Dis 2003;37(1):101–12.
  72. Jindani A, Nunn AJ, Enarson DA. Two 8-month regimens of chemotherapy for treatment of
    newly diagnosed pulmonary tuberculosis: international multicentre randomised trial. Lancet
    2004;364(9441):1244–51.
  73. Okwera A, Johnson JL, Luzze H, et al. Comparison of intermittent continuous phase ethambutol
    with two rifampicin containing regimens in human immunodefi ciency virus (HIV) infected adults with
    pulmonary tuberculosis in Kampala, Uganda. Int J Tuberc Lung Dis 2005 (in press).
  74. Mitchison DA. Antimicrobial therapy for tuberculosis: justifi cation for currently recommended treatment
    regimens. Semin Respir Crit Care Med 2004;25(3):307–315.
  75. Frieden TR. What is intermittent treatment and what is the scientifi c basis for intermittency? In: Frieden
    TR, ed. Toman’s tuberculosis. Case detection, treatment and monitoring, 2nd Edition. Geneva:
    World Health Organization, 2004: 130–138.
  76. Controlled trial of 4 three-times-weekly regimens and a daily regimen all given for 6 months for pulmonary
    tuberculosis. Second report: the results up to 24 months. Hong Kong Chest Service/British
    Medical Research Council. Tubercle 1982;63(2):89–98.
  77. Controlled trial of 2, 4, and 6 months of pyrazinamide in 6-month, three-times-weekly regimens for
    smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid,
    rifampin, and pyrazinamide. Results at 30 months. Hong Kong Chest Service/British Medical
    Research Council. Am Rev Respir Dis 1991;143(4 Pt 1):700–6.
  78. Tuberculosis Research Centre. Low rate of emergence of drug resistance in sputum positive patients
    treated with short course chemotherapy. Int J Tuberc Lung Dis 2001;5(1):40–5.
  79. Bechan S, Connolly C, Short GM, Standing E, Wilkinson D. Directly observed therapy for tuberculosis
    given twice weekly in the workplace in urban South Africa. Trans R Soc Trop Med Hyg
    1997;91(6):704–7.
  80. Caminero JA, Pavon JM, Rodriguez de Castro F, et al. Evaluation of a directly observed six months
    fully intermittent treatment regimen for tuberculosis in patients suspected of poor compliance. Thorax
    1996;51(11):1130–3.
  81. Cao JP, Zhang LY, Zhu JQ, Chin DP. Two-year follow-up of directly-observed intermittent regimens
    for smear-positive pulmonary tuberculosis in China. Int J Tuberc Lung Dis 1998;2(5):360–4.
  82. Rieder HL. What is the evidence for tuberculosis drug dosage recommendations? In: Frieden TR, ed.
    Toman’s tuberculosis. Case detection, treatment and monitoring, 2nd Edition. Geneva: World Health
    Organization, 2004:141–143.
  83. Rieder HL. What is the dosage of drugs in daily and intermittent regimens? In: Frieden TR, ed.
    Toman’s tuberculosis. Case detection, treatment and monitoring, 2nd Edition. Geneva: World Health
    Organization, 2004:139–140.
  84. Blomberg B, Spinaci S, Fourie B, Laing R. The rationale for recommending fi xed-dose combination
    tablets for treatment of tuberculosis. Bull World Health Organ 2001;79(1):61–8.
  85. Panchagnula R, Agrawal S, Ashokraj Y, et al. Fixed dose combinations for tuberculosis: Lessons
    learned from clinical, formulation and regulatory perspective. Methods Find Exp Clin Pharmacol
    2004;26(9):703–21.
  86. World Health Organization. Adherence to long-term therapies. Evidence for action. Geneva: World
    Health Organization, 2003.
  87. Mitchison DA. How drug resistance emerges as a result of poor compliance during short course
    chemotherapy for tuberculosis. Int J Tuberc Lung Dis 1998;2(1):10–5.
  88. Volmink J, Garner P. Directly observed therapy for treating tuberculosis. Cochrane Database Syst
    Rev 2003(1):CD003343.
  89. Volmink J, Matchaba P, Garner P. Directly observed therapy and treatment adherence. Lancet
    2000;355(9212):1345–50.
  90. Chaulk CP, Kazandjian VA. Directly observed therapy for treatment completion of pulmonary tuberculosis:
    Consensus Statement of the Public Health Tuberculosis Guidelines Panel. JAMA
    1998;279(12):943–8.
  91. Sbarbaro J. What are the advantages of direct observation of treatment? In: Frieden TR, ed. Toman’s
    tuberculosis. Case detection, treatment and monitoring, 2nd Edition. Geneva: World Health Organization,
    2004: 183–184.
  92. Sbarbaro J. How frequently do patients stop taking treatment prematurely? In: Frieden TR, ed.
    Toman’s tuberculosis. Case detection, treatment and monitoring, 2nd Edition. Geneva: World Health
    Organization, 2004: 181–182.
  93. Pope DS, Chaisson RE. TB treatment: as simple as DOT? Int J Tuberc Lung Dis 2003;7(7):611–5.
  94. Gordon AL. Interventions other than direct observation of therapy to improve adherence of tuberculosis
    patients: a systematic review: University of California, Berkeley, Master’s Thesis, Spring 2005.
  95. World Health Organization. An Expanded DOTS Framework for Effective Tuberculosis Control. Geneva:
    World Health Organization, 2002.
  96. World Health Organization. The Global Plan to Stop Tuberculosis. Geneva: World Health Organization,
    2001.
  97. Frieden TR. Can tuberculosis be controlled? Int J Epidemiol 2002;31(5):894–9.
  98. World Health Organization. Integrated Management of Adolescent and Adult Illness (IMAI): Acute
    Care. Geneva: World Health Organization, 2004.
  99. World Health Organization. Integrated Management of Adolescent and Adult Illness (IMAI): Chronic
    HIV care with ARV therapy. Geneva: World Health Organization, 2004.
  100. World Health Organization. Integrated Management of Adolescent and Adult Illness (IMAI): General
    principles of good chronic care. Geneva: World Health Organization, 2004.
  101. Santha T. How can the progress of treatment be monitored? In: Frieden TR, ed. Toman’s tuberculosis.
    Case detection, treatment and monitoring, 2nd Edition. Geneva: World Health Organization,
    2004: 250–252.
  102. Maher D, Raviglione MC. Why is a recording and reporting system needed, and what system is recommended?
    In: Frieden TR, ed. Toman’s tuberculosis. Case detection, treatment and monitoring,
    2nd Edition. Geneva: World Health Organization, 2004: 270–273.
  103. Bock N, Reichman LB. Tuberculosis and HIV/AIDS: Epidemiological and Clinical Aspects (World
    Perspective). Semin Respir Crit Care Med 2004;25(3):337–44.
  104. World Health Organization. TB/HIV: A clinical manual. Geneva: World Health Organization, 2004.
  105. World Health Organization. Scaling up antiretroviral therapy in resource-limited settings. Guidelines
    for a public health approach. Geneva: World Health Organization, 2002.
  106. Nunn P, Williams B, Floyd K, Dye C, Elzinga G, Raviglione M. Tuberculosis control in the era of HIV.
    Nat Rev Immunol 2005;5(10):819–26.
  107. UNAIDS/WHO. UNAIDS/WHO Policy Statement on HIV Testing: UNAIDS, 2004: 1–3.
  108. El-Sadr WM, Perlman DC, Denning E, Matts JP, Cohn DL. A review of effi cacy studies of 6-month
    short-course therapy for tuberculosis among patients infected with human immunodefi ciency virus:
    differences in study outcomes. Clin Infect Dis 2001;32(4):623–32.
  109. Harries A. How does treatment of tuberculosis differ in persons infected with HIV? In: Frieden TR, ed.
    Toman’s tuberculosis. Case detection, treatment and monitoring, 2nd Edition. Geneva: World Health
    Organization, 2004: 169–172.
  110. Hopewell PC, Chaisson RE. Tuberculosis and human immunodefi ciency virus infection. In: Reichman
    LB, Hershfi eld ES, eds. Tuberculosis: a comprehensive international approach, 2nd Edition. New
    York: Marcel Dekker, Inc., 2000: 525–552.
  111. Dlodlo RA, Fujiwara PI, Enarson DA. Should tuberculosis treatment and control be addressed differently
    in HIV-infected and -uninfected individuals? Eur Respir J 2005;25(4):751–7.
  112. Chimzizi R, Gausi F, Bwanali A, et al. Voluntary counselling, HIV testing and adjunctive cotrimoxazole
    are associated with improved TB treatment outcomes under routine conditions in Thyolo District,
    Malawi. Int J Tuberc Lung Dis 2004;8(5):579–85.
  113. Chimzizi RB, Harries AD, Manda E, Khonyongwa A, Salaniponi FM. Counselling, HIV testing and
    adjunctive cotrimoxazole for TB patients in Malawi: from research to routine implementation. Int J
    Tuberc Lung Dis 2004;8(8):938–44.
  114. Grimwade K, Sturm AW, Nunn AJ, Mbatha D, Zungu D, Gilks CF. Effectiveness of cotrimoxazole
    prophylaxis on mortality in adults with tuberculosis in rural South Africa. AIDS 2005;19(2):163–8.
  115. Mwaungulu FB, Floyd S, Crampin AC, et al. Cotrimoxazole prophylaxis reduces mortality in human
    immunodefi ciency virus-positive tuberculosis patients in Karonga District, Malawi. Bull World Health
    Organ 2004;82(5):354–63.
  116. Zachariah R, Spielmann MP, Chinji C, et al. Voluntary counselling, HIV testing and adjunctive cotrimoxazole
    reduces mortality in tuberculosis patients in Thyolo, Malawi. AIDS 2003;17(7):1053–61.
  117. Zachariah R, Spielmann MP, Harries AD, Gomani P, Bakali E. Cotrimoxazole prophylaxis in HIV-infected
    individuals after completing anti-tuberculosis treatment in Thyolo, Malawi. Int J Tuberc Lung
    Dis 2002;6(12):1046–50.
  118. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis.
    (WHO/htm/tb/2006.361) Geneva: World Health Organization, 2005.
  119. Coninx R, Mathieu C, Debacker M, et al. First-line tuberculosis therapy and drug-resistant Mycobacterium
    tuberculosis in prisons. Lancet 1999;353(9157):969–73.
  120. Edlin BR, Tokars JI, Grieco MH, et al. An outbreak of multidrug-resistant tuberculosis among hospitalized
    patients with the acquired immunodefi ciency syndrome. N Engl J Med 1992;326(23):1514–21.
  121. Fischl MA, Uttamchandani RB, Daikos GL, et al. An outbreak of tuberculosis caused by multiple-drugresistant
    tubercle bacilli among patients with HIV infection. Ann Intern Med 1992;117(3):177–83.
  122. Schaaf HS, Van Rie A, Gie RP, et al. Transmission of multidrug-resistant tuberculosis. Pediatr Infect
    Dis J 2000;19(8):695–9.
  123. World Health Organization. Anti-tuberculosis drug resistance in the world. Third Report. The WHO/
    IUATLD project on anti-tuberculosis drug resistance surveillance. Geneva: World Health Organization,
    2004.
  124. Caminero JA. Management of multidrug-resistant tuberculosis and patients in retreatment. Eur
    Respir J 2005;25(5):928–36.
  125. Mukherjee JS, Rich ML, Socci AR, et al. Programmes and principles in treatment of multidrug-resistant
    tuberculosis. Lancet 2004;363(9407):474–81.
  126. Kim SJ. Drug-susceptibility testing in tuberculosis: methods and reliability of results. Eur Respir J
    2005;25(3):564–9.
  127. Etkind SC, Veen J. Contact follow-up in high and low-prevalence countries. In: Reichman LB, Hershfi
    eld ES, eds. Tuberculosis: a comprehensive international approach, 2nd Edition. New York: Marcel
    Dekker, Inc., 2000: 377–399.
  128. Rieder HL. Contacts of tuberculosis patients in high-incidence countries. Int J Tuberc Lung Dis
    2003;7(12 Suppl 3):S333–6.
  129. Mohle-Boetani JC, Flood J. Contact investigations and the continued commitment to control tuberculosis.
    (Editorial). JAMA 2002;287:1040.
  130. Reichler MR, Reves R, Bur S, et al. Evaluation of investigations conducted to detect and prevent
    transmission of tuberculosis. JAMA 2002;287(8):991–5.
  131. Morrison JL, Pai M, Hopewell P. Yield of tuberculosis contact investigations within households in
    high incidence countries: a systematic review [Abstract 239]. Infectious Diseases Society of America
    (IDSA) 43rd Annual Meeting 2005, San Francisco, October 6–9, 2005.
  132. Perkins MD. New diagnostic tools for tuberculosis. Int J Tuberc Lung Dis 2000;4(12 Suppl 2):S182-8.
  133. O’Brien RJ, Spigelman M. New drugs for tuberculosis: current status and future prospects. Clin
    Chest Med 2005;26(2):327–40, vii.
  134. Brennan MJ. The tuberculosis vaccine challenge. Tuberculosis 2005;85(1-2):7–12.

Contact information:

Philip C. Hopewell, MD
University of California, San Francisco
San Francisco General Hospital
San Francisco, CA 94110, USA
Email: [email protected]

This file available as a pdf download (1.89 mb)

The ISTC “Patients Charter for Tuberculosis Care, Patients Rights and Responsibilities” is also available for download. (989kb)


Tuberculosis Coalition for Technical Assistance. International Standards for Tuberculosis Care (ISTC). The Hague: Tuberculosis Coalition for Technical Assistance, 2006.

1 ... 7 8 9 10 11 12 13 14 15 16 17 Previous page Back